USPTO Examiner LANDAU SHARMILA GOLLAMUDI - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19003326COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND CONDITIONS INCLUDING ECZEMADecember 2024May 2025Allow401YesNo
17915306PHARMACEUTICAL COMPOSITION COMPRISING NEW LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING RESPIRATORY DISEASE AND USE THEREOFSeptember 2022April 2025Allow3011YesNo
17850041CELL POPULATION COMPRISING MESENCHYMAL STEM CELLS DERIVED FROM FETAL APPENDAGE, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITIONJune 2022May 2024Abandon2220YesNo
17662289SMALL MOBILE STEM CELLS (SMS) AND USES THEREOFMay 2022August 2024Abandon2711NoNo
17630177MUTANT GLUCOSE OXIDASE (GOD) HAVING IMPROVED THERMAL STABILITY AND GENE AND APPLICATION THEREOFJanuary 2022September 2025Allow4320NoNo
17435345METHODS AND MATERIALS FOR BIOLOGICAL IMMOBILIZATION IN MICROFLUIDICSAugust 2021April 2024Abandon3211NoNo
17428510PROBIOTIC COMPOSITIONS COMPRISING LACTOBACILLUS REUTERI STRAINS AND METHODS OF USEAugust 2021August 2025Allow4920NoNo
17328089BREVUNDIMONAS STRAIN AS ENDOSYMBIONT OF VERTICILLIUM DAHLIAE AND USE THEREOFMay 2021July 2023Abandon2610NoNo
17245935METHODS AND MATERIALS FOR TREATING NERVE INJURIES AND NEUROLOGICAL DISORDERSApril 2021April 2024Abandon3621NoNo
17219986DUAL-MODALITY NANOPROBE TARGETING GLIOBLASTOMA AND PREPARATION METHOD THEREOFApril 2021June 2023Abandon2620NoNo
17199376SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROWMarch 2021March 2024Abandon3620NoNo
17155135FloraTummys Probiotic Quick Dissolve TabletMarch 2021October 2023Abandon3310NoNo
17172923GLYCOSIDE HYDOLASES AND THEIR USE IN PREVENTING AND/OR TREATING A PATHOGENIC INFECTION IN AN ANIMALFebruary 2021May 2024Abandon3921NoNo
17135544Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other DisordersDecember 2020October 2023Abandon3301NoNo
17068914METHODS FOR DETERMINING A DRUG DOSING REGIMENOctober 2020August 2023Abandon3510NoNo
16942724Immobilized Enzymatic Digestion of Blood Products for Diagnostic TestingJuly 2020October 2023Abandon3810NoNo
16900163METHOD FOR IDENTIFYING OF A BIOLOGICAL SAMPLE OF A MAMMAL, COMPOSITION FOR USE IN THIS METHOD AND KIT FOR PERFORMANCE OF THIS METHODJune 2020January 2024Abandon4320NoNo
16885323SELF-IMMOLATIVE PROBES FOR ENZYME ACTIVITY DETECTIONMay 2020October 2022Allow2800NoNo
15931772METHOD FOR PRODUCING LACTIC ACID AND METHOD FOR PRODUCING POLYLACTIC ACIDMay 2020January 2023Allow3210YesNo
16761811ENZYME COMPOSITION FOR SUGAR METABOLIC REGULATIONMay 2020April 2023Abandon3630NoNo
16760978ENGINEERED BACTERIA EXPRESSING RACEMASE FOR TREATING DISEASES ASSOCIATED WITH HYPERAMMONEMIAMay 2020December 2022Abandon3201NoNo
16847716OPTIMIZED METHOD FOR DECONTAMINATING PRODUCTION OF GLUCOSE POLYMERS AND GLUCOSE POLYMER HYDROLYZATESApril 2020June 2023Abandon3810NoNo
16843976METHOD FOR PREPARING RHAMNOLIPIDSApril 2020October 2021Abandon1810NoNo
16843942METHOD FOR PREPARING ACTIVE PROTEIN HYDROLYSATES BY HYDROLYZING CEREAL PROTEINS WITH MALT TOGETHER WITH PROTEASESApril 2020October 2021Abandon1810NoNo
16652949CELLULAR TRANSPORT SYSTEM FOR TRANSFERRING A SULFONIC ACID CONSTRUCT CARRYING A CARGO INTO THE CYTOPLASM OF A CELLApril 2020January 2023Allow3301YesNo
16800541SYSTEM AND METHOD OF BIOCATALYTIC CONVERSION FOR PRODUCTION OF ALCOHOLS, KETONES, AND ORGANIC ACIDSFebruary 2020March 2023Abandon3720NoNo
16745097MULTI-COMPONENT ELECTROSPUN FIBER SCAFFOLDSJanuary 2020January 2023Abandon3630NoNo
16737306BLOOD SEPARATION METHODJanuary 2020December 2023Abandon4721YesNo
16705379METHODS FOR TREATING AND PREVENTING C. DIFFICILE INFECTIONDecember 2019August 2023Abandon4430YesYes
16698306ELECTROCHEMICAL CONTROL OF REDOX POTENTIAL IN BIOREACTORSNovember 2019April 2022Abandon2820NoNo
16615164ARRANGEMENT, METHOD AND MEASUREMENT INDICATOR FOR UREA DETERMINATIONNovember 2019December 2022Abandon3701NoNo
16674770SYSTEM AND METHOD FOR DETECTING NEURAL INJURYNovember 2019December 2023Abandon4930YesNo
16548720COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITIONAugust 2019June 2023Abandon4620NoNo
16469845METHOD FOR PROMOTING EXPRESSION OF INSULIN RECEPTOR SUBSTRATE-2June 2019December 2022Abandon4220NoNo
16342677Method, Medium and Kit for Detecting Multiple Aminoglycoside Resistance Including 16S rRNA Methylase Mediated Resistance in Gram-Negative BacteriaApril 2019October 2021Abandon3001NoNo
16375919Pharmaceutical Compositions Containing Cannabis, Uses Thereof and Methods for Improving Digestion and/or Treating Symptoms Associated with Gastrointestinal ComplicationsApril 2019February 2022Abandon3411NoNo
16338017METABOLIC RESTRICTION IN CELL-BASED ASSAYSMarch 2019November 2021Abandon3220NoNo
16336889METHODS AND DEVICESMarch 2019November 2021Abandon3211NoNo
16334670METHOD FOR PRODUCING ASTAXANTHINMarch 2019November 2021Abandon3220NoNo
16355110COMPOSITIONS AND METHODS FOR MONITORING PROGRESSION AND REGRESSION OF DISEASE IN PATIENTS IN RESPONSE TO THERAPYMarch 2019February 2024Abandon5980YesNo
16298695Methods for Detecting Microorganisms Using Microorganism Detection Protein and Other Applications of Cell Binding ComponentsMarch 2019July 2022Allow4031YesNo
16284035METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTSFebruary 2019January 2023Allow4731YesNo
16250672TWO PHASE SUSTAINABLE PHOTOPRODUCTION VIA CO-CULTIVATION OF ENCAPSULATED, CARBOHYDRATE-PRODUCING CYANOBACTERIAJanuary 2019June 2021Abandon2911NoNo
16303578METHODS OF PREVENTING PLATELET ALLOIMMUNIZATION AND ALLOIMMUNE PLATELET REFRACTORINESS AND INDUCTION OF TOLERANCE IN TRANSFUSED RECIPIENTSNovember 2018December 2022Abandon4941NoNo
16099834MESH-BASED IN SITU CROSS-LINKABLE COMPOSITIONSNovember 2018April 2022Abandon4120NoNo
16085566Biofuel generationSeptember 2018October 2020Abandon2501NoNo
16123802DIETARY SUPPLEMENTS AND FORMULATIONSSeptember 2018July 2021Abandon3400NoNo
16075059New Streptococcal ProteasesAugust 2018June 2023Allow5941YesNo
15996916Extracellular Matrix-Derived Gels and Related MethodsJune 2018November 2021Abandon4101NoNo
15735107CELLULOSIC BIOFUEL AND CO-PRODUCTSMay 2018November 2020Abandon3511NoNo
15903714EGG WHITE PROCESSINGFebruary 2018June 2023Abandon6051YesNo
15795383BLOOD COAGULATION ANALYSIS METHOD, BLOOD COAGULATION ANALYZER, AND COMPUTER PROGRAMOctober 2017November 2018Abandon1300NoNo
15565987CROSSLINKED POLYMER STRUCTURE AND USE FOR SAMEOctober 2017April 2021Abandon4240YesNo
15724981Method for Collecting Rare CellsOctober 2017November 2018Abandon1400NoNo
15699047METHOD OF MAPPING GLYCANS OF GLYCOPROTEINSSeptember 2017March 2021Abandon4221NoNo
15678144METHOD OF DETECTING INVASIVE FUNGI ACCORDING TO MORPHOLOGY THEREOF BASED ON CONTRAST STAINING, AND KIT FOR SAMEAugust 2017March 2021Abandon4321NoNo
15675953CAPACITIVE BIOSENSOR FOR IDENTIFYING A MICROORGANISM OR DETERMINING ANTIBIOTIC SUSCEPTIBILITYAugust 2017February 2021Abandon4231NoNo
15550537PROCESS COMPRISING SULFUR DIOXIDE AND/OR SULFUROUS ACID PRETREATMENT AND ENZYMATIC HYDROLYSISAugust 2017June 2023Abandon6051YesYes
15633017FORMULATIONS FOR WOUND THERAPYJune 2017March 2021Abandon4430NoNo
15631530MATRIX CONSTRUCTIONJune 2017October 2019Abandon2721NoNo
15627474SYSTEM AND PROCESS FOR LYSING A BIOLOGICAL SAMPLEJune 2017October 2020Abandon4021NoNo
15454003DIRECTED EVOLUTION USING TURBIDOSTAT FOR INCREASED SPECIFIC GROWTH RATE AND REDUCED LIGHT-HARVESTING ANTENNA SIZE OF PHOTOSYNTHETIC MICROORGANISMS FOR INCREASED PHOTOSYNTHETIC EFFICIENCYMarch 2017January 2021Abandon4631NoNo
15439650PROCESS TO CREATE 3D TISSUE SCAFFOLD USING ELECTROSPUN NANOFIBER MATRIX AND PHOTOSENSITIVE HYDROGELFebruary 2017July 2020Allow4130YesNo
15437948CHOLINERGIC ANTAGONISM AS AN ADJUNCT TO CANCER THERAPYFebruary 2017March 2021Abandon4931NoNo
15431530Lanthanide-Doped Nanoparticle Compositions for Detecting MicroorganismsFebruary 2017February 2021Abandon4841YesNo
15323119TISSUE MODEL, METHOD FOR PRODUCING SAID TISSUE MODEL, AND USE OF SAID TISSUE MODELDecember 2016January 2023Abandon6061YesNo
15091715BIOLOGICAL SAMPLE MEASUREMENT DEVICE, BIOLOGICAL SAMPLE MEASUREMENT SYSTEM, AND BIOLOGICAL SAMPLE MEASUREMENT METHODApril 2016February 2021Abandon5861YesNo
15090019METHOD OF MANUFACTURING AN AFOD INTRAVENOUS INJECTION FROM FRACTION IV TO PREVENT AND KILL HIV-1 AND HIV-2April 2016March 2021Abandon5921NoNo
14925987MICROORGANISM CULTURING MATERIAL AND METHOD FOR DETECTING MICROORGANISMSOctober 2015January 2021Abandon6041YesNo
12598047MULTIPOTENT STEM CELLS AND USES THEREOFOctober 2015September 2017Abandon6051YesYes
14782887METHOD AND COMPOSITION FOR TREATING INFLAMMATORY BOWEL DISEASE WITHOUT COLECTOMYOctober 2015November 2018Abandon3701NoNo
14777397USE OF MICROPARTICLES AND ENDOTHELIAL CELLS WITH DECELLULARIZED ORGANS AND TISSUESSeptember 2015November 2020Abandon6040NoNo
14839763FERMENTATION SYSTEM FOR DRY MILL PROCESSESAugust 2015April 2021Abandon6090YesNo
14758909PROCESSING BIOMASSJuly 2015March 2021Abandon6061NoNo
14716988ENGINEERED STEM CELL THERAPY FOR CARDIAC REPAIRMay 2015April 2019Abandon4621NoNo
14684129SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEApril 2015October 2020Abandon6060YesYes
14573529TISSUE TRANSPLANT COMPOSITIONS AND METHODS FOR USEDecember 2014September 2016Abandon2110NoNo
14550579STARCH PROCESSNovember 2014November 2018Abandon4811NoNo
14548581Dedifferentiation and Reprogramming of CellsNovember 2014April 2017Abandon2810NoNo
14534490Method for Producing Hydrocarbons and Oxygen-containing Compounds from BiomassNovember 2014September 2018Abandon4720NoNo
14398324SCAFFOLDOctober 2014September 2017Abandon3501NoNo
14521583Cosmetic PreparationsOctober 2014January 2017Abandon2710NoNo
14473886Chymosin for the Prevention and Treatment of Gastrointestinal DisordersAugust 2014August 2018Abandon4830NoNo
14381503TREATMENT OF BIOMASSAugust 2014September 2018Abandon4930NoNo
14241872ISOLATING AND THERAPEUTIC USE OF PERIVASCULAR MEDICINAL CELLSJuly 2014March 2021Abandon6051YesNo
14244761PRIMITIVE AND PROXIMAL HEPATIC STEM CELLSApril 2014April 2017Abandon3711YesNo
14185129Body Weight Gain Suppresing Composition and Food Product Comprising the SameFebruary 2014August 2016Abandon3001NoNo
14183599Methods for preventing and/or treating nasal polyps and rhinosinusitisFebruary 2014February 2017Abandon3621NoNo
14110230AUTOLOGOUS HUMAN ADULT PLURIPOTENT VERY SMALL EMBRYONIC-LIKE (hVSEL) STEM CELL REGENERATION OF BONE AND CARTILAGEDecember 2013September 2016Abandon3611NoNo
14105698Sequential Fermentation of Hydrolsate and Solids from a Dilute Acid Hydrolysis of Biomass to Produce Fermentation ProductsDecember 2013August 2016Abandon3301NoNo
14125622METHOD FOR PREPARING MICROVESICULAR ADAM15December 2013August 2016Abandon3301NoNo
14068476Method and Composition for Skin GraftsOctober 2013February 2017Abandon3911NoNo
14002718APPARATUS, SYSTEM, AND METHOD FOR CREATING BIOLOGICALLY PROTECTED/ENHANCED SPACES IN VIVOOctober 2013August 2016Abandon3601NoNo
14051164Use of Stem Cells to Reduce Leukocyte ExtravasationOctober 2013June 2024Abandon6061NoYes
14040356MATERIALS AND METHODS FOR CONVERTING BIOMASS TO BIOFUELSeptember 2013August 2018Abandon5960YesNo
14034353Muscodor Albus Strain Producing Volatile Organic Compounds and Methods of UseSeptember 2013October 2018Abandon6031NoNo
14031926CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTSSeptember 2013October 2017Abandon4921NoYes
13799849MULTIPOTENT STEM CELLS AND USES THEREOFMarch 2013September 2017Abandon5530YesYes
13814823PROCESS FOR THE CONVERSION OF BIOMASS OF PLANT ORIGIN, AND A COMBUSTION PROCESSFebruary 2013September 2018Allow6041NoYes
13695411SCREENING METHODS, COMPOSITIONS IDENTIFIED THEREBY, TOOLS USEFUL FOR THE IDENTIFICATION THEREOF, AND CELL POPULATIONS PRODUCED THEREBYJanuary 2013August 2016Abandon4631NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LANDAU, SHARMILA GOLLAMUDI.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
8
(80.0%)
Examiner Reversed
2
(20.0%)
Reversal Percentile
31.1%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
30
Allowed After Appeal Filing
2
(6.7%)
Not Allowed After Appeal Filing
28
(93.3%)
Filing Benefit Percentile
12.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 6.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LANDAU, SHARMILA GOLLAMUDI - Prosecution Strategy Guide

Executive Summary

Examiner LANDAU, SHARMILA GOLLAMUDI works in Art Unit 1653 and has examined 129 patent applications in our dataset. With an allowance rate of 10.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner LANDAU, SHARMILA GOLLAMUDI's allowance rate of 10.1% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LANDAU, SHARMILA GOLLAMUDI receive 2.90 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LANDAU, SHARMILA GOLLAMUDI is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +11.8% benefit to allowance rate for applications examined by LANDAU, SHARMILA GOLLAMUDI. This interview benefit is in the 47% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 2.7% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 8.5% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 28.6% of appeals filed. This is in the 3% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.